Wells Fargo & Company Gracell Biotechnologies Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.43 - $10.04 $1,069 - $4,417	440 Added 6.51%	7,194 $72,000
Q3 2023 Nov 13, 2023	SELL	$2.83 - $4.9 $9,777 - $16,929	-3,455 Reduced 33.84%	6,754 $19,000
Q2 2023 Aug 15, 2023	BUY	$1.45 - $6.07 $8,243 - $34,507	5,685 Added 125.66%	10,209 $38,000
Q1 2023 May 12, 2023	BUY	$1.8 - $2.5 $1,609 - $2,235	894 Added 24.63%	4,524 $8,000
Q4 2022 Feb 13, 2023	SELL	$2.08 - $3.96 $2,080 - $3,960	-1,000 Reduced 21.6%	3,630 $8,000
Q3 2022 Nov 14, 2022	SELL	$2.08 - $5.15 $1,060 - $2,626	-510 Reduced 9.92%	4,630 $15,000
Q2 2022 Aug 12, 2022	SELL	$1.95 - $5.5 $8,580 - $24,200	-4,400 Reduced 46.12%	5,140 $28,000
Q1 2022 May 16, 2022	BUY	$1.83 - $5.52 $6,642 - $20,037	3,630 Added 61.42%	9,540 $22,000
Q4 2021 Feb 14, 2022	SELL	$5.65 - $14.9 $42,680 - $112,554	-7,554 Reduced 56.11%	5,910 $36,000
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $133,329 - $199,657	13,454 Added 134540.0%	13,464 $187,000
Q2 2021 Aug 16, 2021	SELL	$9.75 - $18.42 $75,094 - $141,870	-7,702 Reduced 99.87%	10 $0
Q1 2021 May 13, 2021	BUY	$14.7 - $30.57 $113,366 - $235,755	7,712 New	7,712 $119,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.